NDA 219209 · Vertex Pharms INC
Journavx
Suzetrigine · Oral · Sodium Channel Blocker
NovelBreakthrough therapyPriority reviewCDER novel approval, Jan 30, 2025: To treat moderate to severe acute pain
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 30, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
60
15 Phase 3, 9 recruiting
FAERS reports
1,649
222 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 2, 2026.
JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. ( 1 )
Mechanism: Suzetrigine is a selective blocker of the Na V 1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (Na V 1.1 through 1.9). Na V 1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting Na V 1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of Na V 1.8 than suzetrigine by 3.7-fold.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 30, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- JOURNAVX · SUZETRIGINE 50MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Suzetrigine" as an intervention, any sponsor and status, largest first.
- Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an AbdominoplastyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05558410 · 1,118 participants · Start Oct 10, 2022 · Primary completion Aug 25, 2023
Drug: Suzetrigine (SUZ); HB/APAP and 2 more · For: Acute Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 12 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a BunionectomyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05553366 · 1,075 participants · Start Oct 3, 2022 · Primary completion Dec 15, 2023
Drug: SUZ; HB/APAP and 2 more · For: Acute Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 21 sites in all
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07231419 · 734 participants (planned) · Start Nov 21, 2025 · Primary completion Apr 6, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Glendale, Arizona · 75 sites in all
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Pivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06696443 · 455 participants · Start Dec 18, 2024 · Primary completion Jan 25, 2027
Drug: Suzetrigine · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Daphne, Alabama; Scottsdale, Arizona · 65 sites in all
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an AbdominoplastyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05034952 · 303 participants · Start Aug 30, 2021 · Primary completion Dec 5, 2021
Drug: VX-548; HB/APAP and 2 more · For: Acute Pain
Sites: Phoenix, Arizona; Pasadena, California; Pasadena, Maryland · 7 sites in all
- A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a BunionectomyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04977336 · 274 participants · Start Jul 19, 2021 · Primary completion Feb 17, 2022
Drug: VX-548; HB/APAP and 2 more · For: Acute Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Anaheim, California · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use249
- pruritus190
- rash147
- paraesthesia111
- nausea104
- dizziness93
- drug ineffective82
- muscle spasms78
- fatigue62
- headache57
- somnolence53
- diarrhoea48
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 670 |
| 2026 | 973 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.
Bertoch T, D'Aunno D, McCoun J, et al. · Anesthesiology 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials.
Alvarez-Aguilar P, Picado-Loaiza S · Medicine (Baltimore) 2026 · Systematic Review, Meta-Analysis
- Safety and efficacy of Suzetrigine (VX-548) for acute moderate to severe pain in adults; a systematic review and meta-analysis.
Irfan Q, Zaidi SMM, Zohair M, et al. · J Clin Anesth 2026 · Systematic Review, Meta-Analysis
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.